Table 2.
Adverse events according to Canagliflozin treatment.
| Adverse Event | Canagliflozin | Control | Ratio or Difference | p-Value |
|---|---|---|---|---|
| (n = 45) | (n = 57) | (95% CI) | ||
| Readmission during first year | 10(22.2%) | 29(49.1%) | HR 0.45(0.21–0.96) | 0.039 |
| Readmission during follow-up | 13(28.9%) | 32(56.1%) | HR 0.45 (0.23–0.91) | 0.027 |
| Number of readmissions at follow-up | 0.5 ± 0.9 | 1.3 ±1.8 | Dif 0.8 (0.3–1.4) | 0.009 |
| All-mortality or readmission | 17(37.8%) | 40(70.2%) | HR 0.51 (0.27–0.95) | 0.035 |
| Change in Glycated hemoglobin at 1yr. (%) | −0.06 ± 1.8 | 0.06 ± 2.1 | Dif −0.12 (−1.06–0.83) | 0.81 |
Hazard ratios (HR) and their 95% confidence interval (CI) for each clinical endpoint was calculated using a Multivariate Cox proportional hazards regression analyses adjusted for age, sex, NYHA class, previous hospitalization for heart failure, coronary artery disease and Log NT-ProBNP at discharge.